FindTrial
Sign In

Resistance Training Effects on Gut Microbiome and Cardiometabolic Outcomes

Effects of 6-week Resistance Training Intervention on Gut Microbiome and Cardiometabolic Outcomes in Adults With Overweight and Obesity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04906525
Enrollment
34
Registered
2021-05-28
Start date
2021-05-19
Completion date
2022-09-30
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise Intervention

Keywords

Gut Microbiome, Resistance Training, Physical Activity

Brief summary

The overall objective of this study is to investigate the effects of resistance training on the gut microbiome and cardiometabolic outcomes in adults with overweight and obesity.

Detailed description

The overall objective of this study is to investigate the effects of resistance training on the gut microbiome and cardiometabolic outcomes in adults with overweight and obesity.

Interventions

BEHAVIORALResistance training

Participants will undergo 6 weeks of supervised resistance training

OTHERConventional physical activity guidelines

Participants are given recommendations on physical activity guidelines

Sponsors

University of Missouri-Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-35 years * BMI: 25-45 kg/m2 * Sedentary lifestyle * Consistent diet patterns * Weight-stable (\<4 kg change over the last 3 mo) * Willingness to adhere to resistance training protocol and not change diet * Non-smoker \>1 year or more

Exclusion criteria

* Disabilities preventing adherence to resistance training protocol * Recent start of medications that affect metabolism or appetite * Antibiotics * Diabetes * Drug therapy for coronary artery disease, peripheral artery disease, congestive heart failure, or dyslipidemia * Uncontrolled hypertension and blood pressure ≥ 180/110 * Gastrointestinal disease and/or bariatric surgery * Smoking * Illicit drug use * Pregnant or lactating individuals

Design outcomes

Primary

MeasureTime frameDescription
Change in stool microbiome compositionChange over 6 weeks16s rRNA sequencing
Change in stool microbiome diversityChange over 6 weeks16s rRNA sequencing

Secondary

MeasureTime frameDescription
24hr appetite ratingsOnce at baseline and at the end of 6 week interventionSubjective rating using visual analog scales
Change in Body masschange over 6 weeksMeasured in kg
Short chain fatty acidsChange over 6 weeksAcetate, propionate, and butyrate
Change in blood pressurechange over 6 weeksdiastolic and systolic blood pressure
Fat massChange over 6 weeksbody composition
Fat free massChange over 6 weeksbody composition
Change in glucose regulationchange over 6 weeks2 hour glucose clearance
Hip circumferencechange over 6 weeksanthropometrics
Waist circumferencechange over 6 weeksanthropometrics
Physical activitychange over 6 weekskcalories burned during free living activity measured by accelerometer
Sleep Qualitychange over 6 weeksMeasured using actigraphs
Change in fasting glucosechange over 6 weeksFasting Glucose
Sleep Durationchange over 6 weeksMeasured using actigraphs

Other

MeasureTime frameDescription
Food environment perceptionsbaseline and at the end of 6 week interventionsubjective and objective questionnaires

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026